Page 2 - Immunization Practice News Today

The agency authorized updated Pfizer and Moderna vaccines that are expected to protect against the new omicron strains causing a surge in cases.

The agency authorized updated Pfizer and Moderna vaccines that are expected to protect against the new omicron strains causing a surge in cases.

CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory

CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus (RSV).

Pozelimab reduced hospitalizations, albumin transfusions in CHAPLE disease patients

INDIANA - The FDA has approved Veopoz (pozelimab-bbfg) injection, a complement inhibitor, for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. Veopoz is the first FDA-approved treatment for C ...

WASHINGTON, D.C. – The Center for Disease Control is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased

Bsip/Universal Images Group via Getty Images(WASHINGTON) -- A new immunization to protect infants from respiratory syncytial virus, or RSV was approved by the Centers for Disease Control and Prevention on Thursday. The approved drug called nirsevimab, which will be marketed in the U.S. by Sanofi as Beyfortus, was recommended unanimously by the CDCs Advisory Committee on Immunization Practice for all children under 8 months old and signed off on by CDC director Dr. Mandy Cohen, the last step in t...

Bsip/Universal Images Group via Getty Images(WASHINGTON) -- A new immunization to protect infants from respiratory syncytial virus, or RSV was approved by the Centers for Disease Control and Prevention on Thursday. The approved drug called nirsevimab, which will be marketed in the U.S. by Sanofi as Beyfortus, was recommended unanimously by the CDCs Advisory Committee on Immunization Practice for all children under 8 months old and signed off on by CDC director Dr. Mandy Cohen, the last step in t...

CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus (RSV).